Skip to content
Open access

Rationale and design of randomized, double-blind trial evaluating the efficacy of single-dose HPV vaccine efficacy in women aged 18 to 30: The PRISMA trial.

Nov 2026 · Vaccine · Vol 96, pp. 129236 · 0 citations · 21 references
Medicine

Abstract

Evidence from the Costa Rica HPV Vaccine Trial suggested that a single dose may provide durable protection in young adult women. Subsequent studies confirmed the non-inferiority of one vs. two doses of the main vaccines among young girls. Vaccination of older cohorts might accelerate cervical cancer elimination, especially if a single dose provides adequate protection. Randomized data are needed to support extended-age, single-dose vaccination strategies. Herein, we present the design, rationale and recruitment results of a three-arm, randomized, double-blinded, clinical trial in Costa Rica to evaluate the efficacy of a single dose of the bivalent (Cervarix®) and nonavalent (Gardasil 9®) HPV vaccines compared with an active control (Tdap). 4925 HPV vaccine-naïve women aged 18-30 years old were enrolled, randomized 1:1:1, and followed for 36 months with cervicovaginal self-sampling every six months starting at 12 months, annual blood collection, and oral/anal sampling at selected visits, with high participation rates. Participants attended ~90% of planned study visits and >96% of attendees provided the necessary specimens. The primary endpoint is incident cerviccovaginal HPV16/18 infection persisting ≥6 months among women HPV16/18 DNA-negative at the enrollment and vaccination visits. Secondary endpoints include vaccine efficacy in the intention-to-treat cohort, oral and anal HPV16/18 protection, and immunogenicity profiles. Trial results will inform mathematical models estimating impact and cost-effectiveness of extending single-dose vaccination to adult young women and directly inform policy to enable extended-age, single-dose strategies to accelerate cervical cancer prevention globally. Furthermore, the study will provide the first evidence for single-dose efficacy against anal and oral HPV infection.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.